BACKGROUND: Meconium analysis is a diagnostically sensitive and objective alternative to maternal selfreport for detecting prenatal tobacco exposure. Nicotine and metabolite disposition in meconium is poorly characterized, and correlation of analytes' concentrations with neonatal outcomes is unexplored. Our objectives were to quantify nicotine, cotinine, trans-3Ј-hydroxycotinine (OH-cotinine), nornicotine, norcotinine, and glucuronide concentrations in meconium, identify the best biomarkers of in utero tobacco exposure, compare meconium concentrations of tobaccoexposed and nonexposed neonates, and investigate concentration-outcome relationships.
Tobacco exposure during gestation presents significant health concerns for pregnant women and fetuses. The 2004 Surgeon General's Report, The Health Consequences of Smoking (1 ) , concluded that active smoking during pregnancy is causally linked to premature rupture of membranes, placenta previa, placental abruption, preterm delivery, shortened gestation, fetal growth restriction, and low birth weight. Supporting evidence has depended on maternal self-report to define smoking status; only 3 investigations confirmed smoking status by toxicological analysis (2) (3) (4) . More recent studies relating maternal self-reported tobacco consumption to neonatal outcomes observed increased risk of congenital heart defects (5 ), postnatal infections in preterm infants (6 ) , preterm birth (5, 7, 8 ) , and lower birth weight (5, (7) (8) (9) (10) among tobacco-exposed children. Maternal self-report is often unreliable, as pregnant smokers may deny or underrepresent the extent of tobacco use (11) (12) (13) (14) (15) . Boyd et al. (12 ) found that 26.2% of pregnant, self-identified nonsmokers had saliva cotinine concentrations consistent with active smoking. Inaccurate self-report may influence exposure-outcome correlation results. England et al. (16 ) observed a misclassification bias of 14%-15% when exposure was determined by urinary cotinine concentrations vs maternal self-report.
Identifying nicotine biomarkers in biological specimens provides an alternative to self-reported gestational tobacco use. Meconium, the first neonatal feces, offers several advantages for detecting prenatal tobacco exposure. Meconium formation begins during the twelfth gestational week; therefore, meconium testing potentially reflects second-and/or third-trimester exposure. Accumulation over months yields higher concentrations and a longer detection window than other neonatal matrices, and collection from diapers is easy and noninvasive.
Until recently, only cotinine was identified in meconium (17) (18) (19) (20) (21) (22) . Generally, meconium cotinine is measured by immunoassay, often without chromatographic confirmation. Most cotinine immunoassays cross-react with trans-3Ј-hydroxycotinine (OH-cotinine), 3 but not nicotine or nornicotine (23, 24 ) . Nicotine and metabolite disposition in meconium is unknown, and relationships between biomarker concentrations and neonatal outcomes are unexplored. To date, no threshold to differentiate passive exposure and nonexposure from active tobacco smoking has been proposed.
Our laboratory recently validated the first method for simultaneous quantification of nicotine and 4 metabolites, cotinine, OH-cotinine, nornicotine, and norcotinine, in meconium (25 ) . We employed this liquid chromatography-tandem mass spectrometry (LC-MS/ MS) method to analyze 168 meconium specimens (125 specimens with and without enzymatic hydrolysis and 43 specimens without) to determine nicotine and metabolite presence in meconium and identify which analytes best detect prenatal tobacco exposure. Moreover, we hypothesized that meconium concentrations can accurately differentiate tobacco-exposed from nonexposed neonates and that meconium nicotine and metabolite concentrations can predict neonatal outcomes. Here we present the disposition of 5 nicotine biomarkers in meconium for the first time and compare the results to maternal self-report of tobacco exposure and birth weight, length, head circumference, gestational age, and 1-and 5-min Apgar scores. Furthermore, we propose a cutoff concentration for differentiating active maternal smoking from passive tobacco exposure during gestation.
Materials and Methods

PARTICIPANTS
Women in good postbirth health, age 13-45 years, at 2 major hospitals in Montevideo, Uruguay, were approached during a period of 45 days for study participation. Pereira Rossell Hospital, the main maternity center in the country, and Clínicas Hospital, a university hospital, account for 33% and 15% of births in Montevideo and Uruguay, respectively, and 50% of births in the low and mid-to-low socioeconomic sector. Women provided written informed consent to participate in this institutional review board-approved study. Interviews regarding previous pregnancies, lifestyle, and frequency and amount of alcohol, tobacco, and drug use were conducted within 48 h of delivery (an English translation of the questionnaire is available in the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/ content/vol54/issue12). Neonates were evaluated for birth weight, head circumference, length, general health status, gestational age, and 1-and 5-min Apgar scores soon after birth. Maternal and neonatal demographics, medical history, and health status were obtained from hospital records.
In all, 215 meconium specimens and 61 interviews were available. Interviews may not have been conducted because of unavailability of the mother due to discharge, transfer, refusal, or other reasons. Insufficient meconium or accidents during transport eliminated 47 specimens for analysis.
MECONIUM ANALYSIS
Meconium from the first 48 h was scraped from diapers and stored at Ϫ20°C until shipment, transferred on ice to the National Institute on Drug Abuse, and maintained at Ϫ20°C until analysis. We quantified nicotine and metabolites using LC-MS/MS (25 ) . Briefly, analytes of interest in 0.5 g meconium and deuterated internal standards were extracted by acidified methanol homogenization. We analyzed specimens with and without hydrolysis to quantify total and unconjugated drug concentrations and to estimate percent glucuronidation, if sufficient meconium was available. Overnight hydrolysis was achieved with E. coli type IX-A ␤-glucuronidase. We subjected acidified samples to solid-phase extraction to concentrate analytes and remove matrix components.
We evaluated 2 multiple reaction monitoring transitions per analyte and internal standard. Chromatographic separation was achieved using a binary mobile-phase gradient. The linear dynamic range was 1.25 [limit of quantification (LOQ) for cotinine, OHcotinine, and norcotinine] or 5 (LOQ for nicotine and nornicotine) to 500 ng/g. Coefficients of determination (R 2 ) were Ͼ0.99. Average hydrolysis efficiencies for nicotine-N-glucuronide, cotinine-N-glucuronide, and OH-cotinine-O-glucuronide were 90%, 80%, and 15%, respectively. Analytical recovery was Ͼ76% of nominal target concentrations; intra-and interday imprecision were Ͻ20%.
STATISTICAL ANALYSES
We performed statistical analyses using SPSS for Windows, version 13.0. We used nonparametric analyses, Wilcoxon signed rank tests, and Mann-Whitney tests to compare concentration differences between groups, as concentrations were not normally distributed. Pearson correlations evaluated relationships between meconium concentrations and quantitative neonatal outcome parameters, and 2 tests examined relationships between categorical variables. P values Ͻ0.05 were considered statistically significant.
Results
MECONIUM RESULTS
We analyzed meconium from 168 neonates without enzymatic hydrolysis to quantify unconjugated drug concentrations; sufficient meconium remained for 125 specimens to undergo a second analysis with enzymatic hydrolysis, allowing direct comparison of unconjugated and total drug concentrations. The following results are from 125 paired meconium analyses (Table 1) . Fifty-nine (47.2%) nonhydrolyzed and 60 (48.0%) hydrolyzed specimens had concentrations greater than the LOQs for at least 1 tobacco biomarker. Nicotine was the most prevalent analyte in both hydrolyzed and nonhydrolyzed specimens, followed by OH-cotinine, cotinine, nornicotine, and norcotinine. In 3 specimens, OH-cotinine concentrations exceeded the 500 ng/g upper LOQ. Determining exact concentrations was not possible for these specimens, as insufficient meconium remained for dilution; affected pairs were not included in quantitative comparisons and statistical analyses. In nonhydrolyzed specimens, cotinine was found in the highest concentrations, followed by OHcotinine and nicotine, whereas in hydrolyzed specimens, OH-cotinine was followed by cotinine and nicotine. For the first time, nornicotine and norcotinine were detected in meconium, although in fewer specimens and at concentrations Ͻ25 ng/g. Analyte concentrations obtained before and after enzymatic hydrolysis were compared only in meconium specimens with paired unconjugated and total drug concentrations. Differences between unconjugated and total concentrations were significantly greater than zero for OHcotinine and cotinine (P Ͻ 0.001), indicating substantial glucuronidation of these analytes.
Most specimens were positive for nicotine, cotinine, and/or OH-cotinine. No specimens were positive for nornicotine and/or norcotinine alone (Table 2) . Nornicotine and norcotinine were found in specimens with high nicotine, cotinine, and OH-cotinine concentrations. Median (interquartile range) nicotine, cotinine, and OH-cotinine concentrations were 24.9 (9.1-78.7), 47.6 (18.9 -106.8), and 37.4 (11.6 -107.5) ng/g in nonhydrolyzed specimens, respectively, and 27.4 (10.3-84.1), 47.8 (18.3-116.9) , and 49.8 (15.1-126.5) ng/g in hydrolyzed specimens. Comparing concentrations from hydrolyzed and nonhydrolyzed specimens, median (interquartile range) percentages of glucuronide conjugates were 7.5% (2.1%-16.1%) for nicotine, 15.2% (6.0%-26.8%) for cotinine, and 28.9% (16.2%-46.1%) for OH-cotinine. Nonhydrolyzed concentrations were greater than hydrolyzed concentrations in 3 instances for OH-cotinine, 4 for cotinine, and 13 for nicotine. Wide variations in the degree of glucuronidation were observed for all 3 analytes.
We calculated unconjugated biomarker concentration ratios for each metabolite and nicotine, each metabolite and its direct precursor, and summed metabolites and nicotine. Median (interquartile range) ratios were 1.00 (0.72-1.60) cotinine:nicotine, 1.09 (0.51-2.25) OHcotinine:nicotine, 0.02 (0.01-0.05) norcotinine:nicotine, 0.08 (0.06 -0.10) nornicotine:nicotine, 0.04 (0.01-0.05) norcotinine:cotinine, 1.14 (0.64 -1.78) OH-cotinine:cotinine, and 1.74 (1.41-2.78) total metabolites:nicotine.
MECONIUM NICOTINE BIOMARKER RESULTS VS SELF-REPORTED SMOKING STATUS
Maternal tobacco status questionnaires were available for 49 of 125 paired meconium analyses. Thirty-two women (65.3%) reported no smoking during pregnancy. In the nonsmoking group, no nicotine analytes were detected in 24 nonhydrolyzed (75.0%) and 23 hydrolyzed (71.9%) meconium specimens at the method's LOQ (Table 3 ). In the 8 positive specimens, only nicotine, cotinine, and OH-cotinine were observed, with unconjugated drug concentrations Ͻ10 ng/g in all but 1 specimen that contained 72.4 ng/g nicotine, 29.9 ng/g cotinine, and 27.0 ng/g OH-cotinine.
Seventeen women (34.7%) admitted smoking sometime during pregnancy. Only 3 of these (17.6%) were negative for tobacco biomarkers. Two women reported first-trimester smoking only; since meconium formation begins in the second trimester, detection of nicotine biomarker would not be expected. The mother of the third infant with negative meconium results self-reported smoking 1 to 5 cigarettes daily throughout pregnancy. Unconjugated and total cotinine, unconjugated and total OH-cotinine, and total nicotine concentration distributions were statistically different between smoking and nonsmoking groups, with larger concentrations observed in the smoking group. Norcotinine and nornicotine were quantified in approximately one-third of meconium specimens from the smoking group.
MATERNAL LIFESTYLE CHARACTERISTICS VS SELF-REPORTED SMOKING STATUS
Maternal interviews and meconium unconjugated drug concentrations were available for 61 neonates. Forty-one women denied smoking while pregnant, whereas 17 individuals reported smoking throughout gestation and 3 individuals during the first trimester only. Daily smoking of 1-5 and 6 -10 cigarettes was reported by 73.7% and 26.3% of smokers, respectively. No woman reported smoking more than 10 cigarettes per day. Maternal age and number of children are presented in Table 4 . Maternal lifestyle characteristics, grouped by meconium results, are pre- 
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sented in Table 5 . More nonsmokers were married than smokers (P Ͻ 0.05), but there were no significant differences in educational level, working status, or alcohol use during pregnancy between groups. Thirteen women, 8 nonsmokers and 5 smokers, received tranquilizers during the first 3 months of pregnancy. One nonsmoker and 3 tobacco users reported smoking cannabis during pregnancy, one of whom also consumed cocaine throughout pregnancy. No women reported gestational amphetamine, methamphetamine, hashish, inhalant, ecstasy, heroin, or morphine use.
NEONATAL OUTCOME MEASURES VS SELF-REPORTED SMOKING STATUS AND MECONIUM RESULTS
Neonatal outcome measures were stratified by maternal self-reported tobacco use (yes/no) and meconium nicotine and metabolite results (positive/negative) ( Table 6 ). Meconium was considered positive if at least 1 analyte was greater than the LOQ. No statistically significant differences in neonatal birth parameters were observed when results were classified by maternal self-reported tobacco use. When grouped by nicotine biomarker status, mean head circumference was significantly smaller in children with positive results (P ϭ 0.003), even after controlling for gestational age. The mean difference (95% CI) in head circumference was 1.48 (0.53-2.43) cm. Fifteen children born to 11 nonsmokers and 4 smokers had low birth weight (Ͻ2500 g). Ten were premature (Ͻ37 weeks gestation), 3 self-reported smokers gave birth at 30, 33, and 35 weeks, and 7 nonsmokers delivered at between 35 and 36 weeks. Gestational age, neonatal sex, and 1-and 5-min Apgar scores were similar for each group after stratifying by meconium nicotine results and maternal selfreport status.
CORRELATING MECONIUM CONCENTRATIONS AND NEONATAL
OUTCOME MEASURES
We calculated Pearson correlations for unconjugated nicotine, cotinine, OH-cotinine, norcotinine, and nor- nicotine concentrations and neonatal weight, head circumference, length, gestational age, and 1-and 5-min Apgar scores (Table 7) . No significant correlations were found for unconjugated drug meconium concentrations and neonatal outcomes.
Discussion
These are the first data on the disposition of nicotine, cotinine, OH-cotinine, nornicotine, and norcotinine in meconium. We used a new LC-MS/MS method with sufficient LOQs for simultaneous selective analysis of these analytes. Although other methods have not reported nicotine and OH-cotinine in meconium, we found that these compounds were more prevalent than and as abundant as cotinine (17, 19 ) . Our results are consistent with a recent report identifying nicotine, cotinine, and OH-cotinine in meconium by HPLC with colorimetric detection. In that study, however, nicotine and cotinine were more abundant than OH-cotinine. Prevalence data were not provided (26 ) . Cotinine immunoassays are most commonly employed to determine tobacco exposure in meconium. In our study, however, 18.6% and 15.0% of positive specimens contained only nicotine after nonhydrolyzed and hydrolyzed analyses, respectively, whereas an additional 8% were positive for either OH-cotinine only or OH-cotinine and nicotine in combination. The low OH-cotinine concentrations in these specimens (range 1.3-7.8 ng/g) are not sufficient to generate positive results in a cotinine immunoassay with 30% OHcotinine cross-reactivity at the standard 10 ng/g cutoff. These data suggest that immunoassays may fail to identify approximately 1 in 4 tobacco-exposed neonates. We describe, for the first time, nicotine, cotinine, and OH-cotinine glucuronides in meconium. Cotinine and OH-cotinine are significantly glucuronide bound, whereas nicotine is not. Dempsey et al. (18 ) observed that cotinine detection rates after basic hydrolysis increased from 33% to 79% at a 50 ng/g cutoff using microplate enzyme immunoassay but attributed increases to reversing Schiff base bonds formed between free amino functions on meconium proteins and cotinine, not cotinine glucuronide cleavage. Interestingly, in our study, only 1 additional meconium specimen was identified as positive following hydrolysis. The low LOQ could contribute to the improved ability to detect unconjugated nicotine biomarkers. These data support that time-consuming and costly enzymatic hydrolysis can be eliminated without markedly compromising detection of tobacco-exposed infants.
Hydrolysis yielded higher analyte concentrations in 62.5%, 89.6%, and 92.0% of nicotine-, cotinine-, and OH-cotinine-containing specimens, respectively. In nearly all cases where unconjugated drug concentrations were higher than total drug values, the difference was within the method imprecision. Moreover, 2 separate meconium aliquots were analyzed for unconjugated and total drug concentrations, and despite extensive mixing before weighing, complete homogeneity may not have been achieved.
OH-cotinine total and glucuronide results should be interpreted with caution, as hydrolysis efficiency of authenticated OH-cotinine-O-glucuronide was determined to be 15% during method validation. Possibly, the high degree of OH-cotinine glucuronidation observed in authentic meconium could be due to the presence of N-glucuronide or diglucuronide species, as well as OH-cotinine-O-glucuronide. Human liver microsomes incubated with OH-cotinine are capable of forming both N-and O-glucuronides, although OHcotinine-N-glucuronide has not been reported in adult urine (27, 28 ) . Statistically significant differences in meconium cotinine and OH-cotinine concentrations were observed between exposed-and nonexposed neonates. These results are consistent with studies showing differences in meconium cotinine concentrations from neonates born to smoking and nonsmoking mothers. (26 ) . Differences in meconium concentrations may reflect differences in study populations, smoking habits, cultural attitudes toward gestational smoking, nicotine cigarette content, and/or analytical variability, including cross-reactivity with other nicotine analytes.
Approximately 30% of participating mothers provided self-reported tobacco smoking histories. This subset of matched meconium specimens and selfreported histories was evaluated for correlations with Establishing a meconium cutoff concentration to identify maternal smoking status is desirable, as selfreport is often unreliable. We investigated the presence of nicotine, cotinine, or OH-cotinine Ͼ10 ng/g in meconium as an effective cutoff, based on the concentration distribution between smoking and nonsmoking groups. Prediction efficiency of prenatal smoking exposure or nonexposure was determined at a variety of cutoff concentrations by ROC curve analysis. The 10 ng/g cutoff had the highest predictive value (93.3%) of potential cutoff concentrations based on maternal selfreport. At a 10 ng/g cutoff, the sensitivity and specificity were 82.4% and 97.0%, respectively. Thirty-two mothers reported no tobacco use during pregnancy, but nicotine biomarkers were measurable in 8 meconium specimens. In 7, analyte concentrations were Ͻ10 ng/g and considered negative. The eighth specimen contained 72.4 ng/g nicotine, 30 .0 ng/g cotinine, and 26.6 ng/g OH-cotinine, concentrations consistent with tobacco exposure. Maternal self-report indicated previous tobacco use but no active smoking during pregnancy. It is possible that this woman did not accurately report her smoking status or that she was exposed to high levels of environmental smoke. Three neonates in the smoking group had negative meconium results; in 2 cases, mothers reported smoking only during the first trimester, before meconium begins to form. In the third case, the woman reported smoking 1-5 cigarettes per day throughout pregnancy. It is unclear why nicotine and/or metabolites were not detected.
The cutoff concentration determination has several limitations. First, maternal self-report was defined as the gold standard. Given that self-reported tobacco consumption by pregnant women may be unreliable (as suspected in at least 1 specimen in this study), the number of false positives could increase due to underreporting of tobacco smoking. Additionally, reported tobacco consumption at any time during pregnancy constituted "exposed," although meconium that begins forming in the second trimester would not detect first-trimester smoking. In this instance, false negatives could be increased. These two biases could decrease, not increase, diagnostic sensitivity, specificity, and effectiveness. The 10 ng/g proposed cutoff achieved a high effectiveness of 93.3% for differentiating nonsmokers and passive smokers from active smokers. Other limitations include unknown extent of environmental participant exposure. Additional evaluation of the proposed cutoff concentration is needed to confirm the effectiveness of the 10 ng/g cutoff.
Nornicotine and norcotinine are biomarkers of active maternal smoking; however, these analytes were present in only one-third of meconium specimens from tobacco-exposed neonates and never in nicotine-, cotinine-, and OH-cotinine-negative specimens, negating their value as better nicotine biomarkers. Nonetheless, it is possible that these analytes could be important predictors of other neonatal nicotine toxicities.
Few studies have correlated cotinine meconium concentrations and adverse neonatal events. Nuesslein et al. (22 ) associated high cotinine concentrations in meconium (that is, greater than the 36.8 g/L population median, as determined by RIA) with lower birth weight and increased risk of upper and lower respiratory infections during the first 6 months of life. In our study, we evaluated for the first time meconium concentrations of nicotine, cotinine, OH-cotinine, nornicotine, and norcotinine as predictors of birth weight, head circumference, length, gestational age, and 1-and 5-min Apgar scores. There were no statistically significant relationships between nicotine and/or metabolite concentrations in meconium and neonatal birth parameters, although the presence of a nicotine biomarker in meconium was associated with decreased head circumference. A limitation of these findings is the sample size of 61 neonatal outcomes. Despite the sample size, these preliminary data are important, as this is the first time that relationships between meconium nicotine and OH-cotinine concentrations and neonatal outcome parameters have been investigated. Women participating in this study were relatively light smokers (Ͻ5 cigarettes daily), which may also explain why no correlation was observed. This level of selfreported cigarette consumption is consistent with the WHO estimate of per capita cigarette consumption in Uruguay (approximately 1300 cigarettes annually or 3.4 cigarettes daily) (29 ) . Although stronger associations between heavy smoking and adverse outcomes have been observed, Jaddoe et al. (7 ) noted significantly lower birth weight in neonates whose mothers smoked Ͻ5 cigarettes per day in late pregnancy compared to nonsmokers. Multiple factors affect fetal growth, including maternal health, nutrition, and drug and alcohol exposure. This study investigated only one potential influence on intrauterine development.
Whereas nicotine and metabolites were identified in meconium, metabolite origin is undetermined. Nicotine, cotinine, OH-cotinine, nornicotine, and norcotinine and glucuronides may cross the placenta and deposit in meconium. Alternatively, nicotine could cross the placenta, be biotransformed by the fetal liver, and deposit in meconium. To date, only nicotine has been experimentally shown to cross the placenta, with 90% entering fetal circulation and 1% converted to cotinine (30, 31 ) . Placental transfer and metabolism of cotinine, OH-cotinine, nornicotine, and norcotinine should be further evaluated, since such data could highlight placental and fetal liver protective mechanisms.
In addition to cotinine, we suggest nicotine, the most prevalent analyte, and OH-cotinine, the most abundant analyte, as effective biomarkers in meconium for monitoring prenatal tobacco exposure.
